Orphan Drugs Industry 2018 Set for 11.56% CAGR | Explosive Growth Seen in Pharmaceutical Sector by 2022 – MarketResearchFuture.com

The Orphan Drugs Market Is Developing Exponentially Owing To The Growing Investment In Research And Development And Unmet Needs For Rare Diseases Are The Key Factor Driving The Orphan Drugs Market. Global Orphan Drug Market, Is Projected To Reach $200 Billion In 2022, Reflecting A Compound Annual Growth Rate (CAGR) Of 11.56%.

Global Orphan Drugs Market is segmented into four major regions including Americas, Europe, Asia Pacific, and Middle East and Africa region.

Globally, the Americas region is considered to be the largest market for orphan drugs. Factors such as the increasing government incentives, and high product demand are expected to promote market growth in the US region, which is reflected to be the highest revenue-generating region in the Americas.

Ask for Sample Report @ https://www.marketresearchfuture.com/sample_request/2312 .

The European regions is the second-largest market for Global orphan drugs. The upcoming market for orphan drugs is predicted to be subjugated by the developed regions with developing regions acting as a support pillar for its growth.

Asia Pacific will be the fastest growing regional market and is likely to be the key to the future. Middle East & Africa is expected to have limited but steady growth in the market.

Celgene Corporation (U.S.), F. Hoffmann- La Roche AG (Switerzland), Alexion Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Takeda Pharmaceuticals Company Limited (Switerzland), Biogen Idec Limited (U.S.), Eli Lilly and Company (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switerzland), Vertex pharmaceuticals, Inc. (U.S.), Sanofi (France), Johnson & Johnson (U.S.), Aegerion Pharmaceuticals, Inc. (U.S.), Amgen Inc. (U.S.), GlaxoSmithKline plc (U.S.), Merck & Co., Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), and others are some of the prominent players at the forefront of competition in the global orphan drugs market and are profiled in MRFR Analysis. 

Orphan Drugs Market - Regional Analysis

The global orphan drugs market is segmented into four major regions including

Americas

Europe

Asia Pacific

Middle East

And Africa region.

Globally, the Americas region is considered to be the largest market for orphan drugs. Factors such as the increasing government incentives, and high product demand are expected to promote market growth in the US region, which is reflected to be the highest revenue-generating region in the Americas.

The European regions is the second-largest market for Global orphan drugs. The upcoming market for orphan drugs is predicted to be subjugated by the developed regions with developing regions acting as a support pillar for its growth.

Asia Pacific will be the fastest growing regional market and is likely to be the key to the future. Middle East & Africa is expected to have limited but steady growth in the market.

Check Discount @ https://www.marketresearchfuture.com/check-discount/2312 .

Industry Updates are:

Jan, 2017 Acucela Inc. received orphan drug FDA approval for emixustat for treatment of Stargardt disease. This approval is anticpated to be essential for the treatment of this genetic disease.

Nov, 2015 Ocata Therapeutics was acquired by Astellas Pharma to expand its product portfolio for treatment of retinal disorders such as age-related macular degeneration and Stargardt disease.

June, 2015 Johns Hopkins University and Bayer Healthcare agreed to sign a five year collaboration agreement for developing treatment for diabetic macular edema, retinal vein occlusion, Stargardt's disease, geographic atrophy, and age-related macular degeneration

March, 2014 Santen Pharmaceuticals contracted a pact with TRACON pharmaceuticals for the development and commercialization of Tracon's anti-VEGF product TRC105, an orphan drug class for the treatment of various eye related disorder

April, 2012 Baush & Lomb acquired Ista Pharmaceuticals for expanding its customer base and gaining pipline drugs for the treatment of Stargardt disease.

Company Overview:

This market is highly fragmented and is dominated by five major vendors including F. Hoffmann La Roche AG, Celgene Corporation, Bristol-Mayer Squibb Company, Novartis AG, and Pfizer Inc. as these are supposed to have extensive product portfolios. Factors such as the stringent rules and regulations, patent expiry of branded drugs, decreased R&D productivity, and high regulatory barriers are some significant challenges to the vendors during the forecast period.

Table of Contents:

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

….TOC CONTINUED

List of Tables:

TABLE 1 GLOBAL ORPHAN DRUGS MARKET, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ORPHAN DRUGS MARKET, BY APPLICATION, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ORPHAN DRUGS MARKET, BY PHARMACOLOGICAL CLASS, 2013-2022 (USD MILLION)

TABLE 4 GLOBAL ORPHAN DRUGS MARKET, BY TECHNOLOGY, 2013-2022 (USD MILLION)

TABLE 5 GLOBAL ORPHAN DRUGS MARKET, BY SOURCE, 2013-2022 (USD MILLION)

TABLE 6 GLOBAL ORPHAN DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)

Have Any Query, Ask to our Expert @ https://www.marketresearchfuture.com/enquiry/2312 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.